Georg Ebersbach (Movement Disorders Clinic, Beelitz-Heilstaetten, Beelitz, Germany) kindly took the time to talk us through the findings of his presentation entitled: Opicapone’s added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson’s disease: a post-hoc analysis of BIPARK-I and II.
ClinicalTrials.gov identifiers for the two large multinational trials included in this post-hoc analysis, that previously demonstrated efficacy and safety of opicapone for end-of-dose motor fluctuations in Parkinson’s disease: NCT01568073 and NCT01227655, respectively.
1. What impact do motor fluctuations have on patients with Parkinson’s disease (PD)? (0:06)
2. Could you give us a brief overview of the main findings of the BIPARK-I and II studies supporting the use of opicapone in PD? (0:47)
3. What was the rationale for the post-hoc analysis you presented? (1:54)
4. What were the findings of this analysis? (2:24)
5. What are the implications of these findings in terms of the optimum use of opicapone in routine clinical practice? (3:35)
Disclosures: Prof. Ebersbach reports receiving honoraria for lectures and advisory board activities from BIAL, the manufacturer of opicapone.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the International Parkinson and Movement Disorder Society MDS Virtual Congress 2020.
Share this Video
Related Videos In Parkinson's Disease
Claudia Trenkwalder, EAN 2021: REM Sleep Behaviour Disorder and Neurodegeneration
touchNEUROLOGY was joined by Prof. Claudia Trenkwalder (Paracelsus-Elena-Hospital, Kassel Germany, University Medical Center, Goettingen, Germany) to discuss her EAN presentation looking into REM Sleep Behaviour Disorder and the connection with neurodegeneration. The abstract entitled: ‘REM Sleep Behaviour Disorder (RBD): future implications for neurodegenerative disease’ was presented at the 7th Congress of the European Academy of […]
Heinz Reichmann, EAN 2021: OPTIPARK Study Findings
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the key real world findings from the OPTIPARK study, investigating the use of Opicapone in the treatment of Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented […]
Heinz Reichmann, EAN 2021: Levodopa-based Drugs in the Treatment of Parkinson’s Disease
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the use of levodopa-based drugs for managing Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!